Hepatitis A Virus Cellular Receptor 1 (HAVcr-1) Initiates Prostate Cancer Progression in Human Cells via Hepatocyte Growth Factor (HGF)-Induced Changes in Junctional Integrity [PDF]
Biomolecules, 2022 Background: HAVcR-1 has been linked to cancer aetiology and may regulate junctional complexes, with its role in prostate cancer still unexplored. This study aims to investigate the expression of HAVcR-1 in prostate cancer samples and the exploration of ...
Emily A. Telford +6 more
doaj +6 more sources
Long non-coding RNA AL139002.1 promotes gastric cancer development by sponging microRNA-490-3p to regulate Hepatitis A Virus Cellular Receptor 1 expression. [PDF]
Bioengineered, 2021 Mounting evidence suggests that lncRNA regulates many important diseases. However, the biological role of most lncRNAs in gastric cancer (GC) remain unclear. In this paper, we determined differential expression of lncRNAs and predicted ceRNA networks in the GC database by bioinformatics analysis and validated in GC cells.
Chen Y, Zhang R.
europepmc +4 more sources
Annals of Hepatology, 2018 Introduction and aim. HAVCR1 protein is the cellular receptor for hepatitis A virus (HAV). Genetic polymorphism in this gene may alter the outcome of HAV infection.
Mercilena Benjamin +5 more
doaj +3 more sources
Effects of General Anesthesia on 2 Urinary Biomarkers of Kidney Injury-Hepatitis A Virus Cellular Receptor 1 and Lipocalin 2-in Male C57BL/6J Mice. [PDF]
J Am Assoc Lab Anim Sci, 2019 Urinary biomarkers are used increasingly for sensitive prediction of kidney injury in preclinical and clinical studies. Given the frequent requirement of anesthesia in various animal models of disease, it is important to define the effects of anesthesia on kidney injury biomarkers to guide the appropriate selection of anesthetic agents and to avoid ...
Gibbs KM +4 more
europepmc +4 more sources
Binding of Hepatitis A Virus to Its Cellular Receptor 1 Inhibits T-Regulatory Cell Functions in Humans [PDF]
Gastroenterology, 2012 CD4+ T-regulatory (Treg) cells suppress immune responses and control self-tolerance and immunity to pathogens, cancer, and alloantigens. Most pathogens activate Treg cells to minimize immune-mediated tissue damage and prevent clearance, which promotes chronic infections. However, hepatitis A virus (HAV) temporarily inhibits Treg-cell functions.
JOSÉ M Casasnovas +2 more
exaly +3 more sources
The interaction of hepatitis A virus (HAV) with soluble forms of its cellular receptor 1 (HAVCR1) share the physiological requirements of infectivity in cell culture [PDF]
Virology Journal, 2009 Background Hepatitis A virus (HAV), an atypical Picornaviridae that causes acute hepatitis in humans, usurps the HAV cellular receptor 1 (HAVCR1) to infect cells. HAVCR1 is a class 1 integral membrane glycoprotein that contains two extracellular domains:
Kaplan Gerardo G +2 more
doaj +3 more sources
The Human Homolog of HAVcr-1 Codes for a Hepatitis A Virus Cellular Receptor [PDF]
Journal of Virology, 1998 ABSTRACT The hepatitis A virus cellular receptor 1 (HAVcr-1) cDNA was isolated from a cDNA expression library of African green monkey kidney (AGMK) cells by using protective monoclonal antibody (MAb) 190/4, which blocks the binding of hepatitis A virus (HAV) to AGMK cells.
Peter Thompson, Gerardo Kaplan
exaly +3 more sources
ZO-2 determines cell membrane localization of receptor NTCP and supports hepatitis B virus infection [PDF]
mBioHepatitis B virus (HBV) infects hepatocytes by using sodium taurocholate cotransporting polypeptide (NTCP) as a receptor. NTCP can render non-permissive hepatocyte cell lines such as HepG2 permissive to HBV infection.
Hironori Nishitsuji +8 more
doaj +2 more sources
Cell Reports, 2023 Summary: Cells activate stress response pathways to survive adverse conditions. Such responses involve the inhibition of global cap-dependent translation.
Meghan T. Harris, Michael T. Marr, II
doaj +1 more source
Viruses, 2021 Laboratory cultivation of viruses is critical for determining requirements for viral replication, developing detection methods, identifying drug targets, and developing antivirals.
Victoria R. Tenge +8 more
doaj +1 more source